XenoPort, Glaxo end collaboration on restless legs syndrome drug – The West … – The West Australian

by admin on November 28, 2012

XenoPort, Glaxo end collaboration on restless legs syndrome drug – The West
The West Australian
(Reuters) – XenoPort Inc said it agreed with its marketing partner GlaxoSmithKline to end their collaboration on Horizant, a drug to treat restless legs syndrome. Glaxo will return all rights to the drug to XenoPort by April 30 and buy $20 million
GSK, XenoPort part ways after Horizant disappointmentFiercePharma

all 29 news articles »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: